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Objective: Endothelial cell dysfunction has been implicated in the inflam-
matory response to cardiopulmonary bypass, and the upregulation of endo-
thelial cell expression of adhesion molecules might promote leukocyte
extravasation in vivo. Soluble endothelial cell adhesion molecules are
increased after bypass. The aim of this study was to investigate the
relationship between endothelial cell-surface expression of adhesion
molecules and their concentration in plasma after coronary artery bypass
grafting.
Methods: Ten patients undergoing coronary artery bypass with cardiopulmo-
nary bypass had 5 plasma samples taken at defined intervals before, during,
and after cardiopulmonary bypass. Plasma was incubated with human
umbilical vein endothelial cell monolayers, and expression of E-selectin,
intercellular adhesion molecule 1, and vascular cell adhesion molecule 1
on the surface of human umbilical vein endothelial cell monolayers was
measured by means of enzyme-linked immunosorbent assay. Plasma soluble
adhesion molecules, C-reactive protein, interleukin 8, interleukin 10, trans-
forming growth factor 1, and neutrophil counts were determined for each
patient.
Results: Markers typical of acute inflammation (ie, interleukin 8, neutro-
phils, and C-reactive protein) were all increased after bypass. Soluble
plasma intercellular and vascular cell adhesion molecule 1 (but not E-selectin)
were increased after bypass. However, endothelial cell expression of vas-
cular cell adhesion molecule 1 and intercellular adhesion molecule 1 (but not
E-selectin) were significantly decreased by exposure to postbypass
plasma. Additionally, postbypass plasma inhibited interleukin 1-stimulated
endothelial cell expression of vascular cell and intercellular adhesion
molecule 1. Interleukin 10 and transforming growth factor 1, both of
which are known to inhibit endothelial cell adhesion molecule
expression, were respectively increased 10-fold and 3-fold (P  .05) after
bypass.
Conclusions: Despite containing increased soluble intercellular and vascular cell
adhesion molecule 1, postbypass plasma inhibits endothelial cell expression of
intercellular and vascular cell adhesion molecule 1. Upregulated vascular ex-
pression of adhesion molecules might not be essential for endothelial activation
after bypass.
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Cardiopulmonary bypass (CPB) is known tocause a systemic inflammatory responsesyndrome, which can contribute to signifi-cant morbidity and mortality.1 The endo-thelial-leukocyte adhesion cascade is cen-tral to the transmigration of activated
leukocytes into the subendothelial space, where they de-
granulate, promoting inflammatory injury. Upregulation of
endothelial cell (EC) adhesion molecule expression occurs
in many inflammatory conditions2-4 and promotes the adhe-
sion and transmigration of leukocytes.
CPB has generally been associated with increased levels
of plasma soluble EC adhesion molecules, which have been
attributed to the activation and injury of ECs.1,5-7 However,
some studies have shown a decrease in soluble adhesion
molecule levels after CPB.8 Whether soluble adhesion mol-
ecules contribute to the causation of the systemic inflam-
matory response syndrome after bypass or are merely a
marker of other inflammatory processes is unclear. Indeed,
they might even have an anti-inflammatory role under some
circumstances.9,10
The relationship between soluble adhesion molecules
and their endothelial expression is not well established.10
This is because adhesion molecules can be expressed on
non-ECs, such as monocytes, tissue macrophages, fibro-
blasts, and dendritic cells,11-15 and because it is difficult to
evaluate EC adhesion molecule expression in human sub-
jects in vivo. The effect of CPB on EC expression of
adhesion molecules might be important for therapeutic tar-
geting of the post-CPB inflammatory response and for un-
derstanding the mechanism of CPB-induced inflammation
within the vascular bed.
The aim of this study was to investigate the relationship
between EC surface expression of adhesion molecules and
their concentration in plasma after coronary artery bypass
grafting (CABG). Although soluble intercellular adhesion
molecule 1 (ICAM-1), soluble vascular cell adhesion mol-
ecule 1 (VCAM-1), and other inflammatory markers are
confirmed to be increased after CPB, post-CPB plasma
downregulates the expression of ICAM-1 and VCAM-1 on
ECs. These observations dissociate the regulation of soluble
and cell-surface adhesion molecules after CPB.
Material and Methods
Patients
Ten adult patients with multivessel coronary artery disease under-
going first-time elective CABG with CPB were enrolled in the
study. The study was undertaken with institutional ethics commit-
tee approval, and written informed consent was obtained from each
patient. Patients taking corticosteroids, nonsteroidal anti-inflam-
matory drugs, aspirin, or other immunosuppressing agents were
excluded, as were patients with diabetes mellitus, renal failure, or
other immunocompromising conditions. Patients receiving intra-
venous nitrates or heparin were also excluded.
Anesthetic, CPB, and Operative Techniques
Anesthesia induction was performed with 15 to 30 g/kg fentanyl,
0.5 to 1 mg/kg thiopentone, and 0.15 mg/kg pancuronium. Anes-
thesia was maintained with a volatile agent (isoflurane) throughout
the procedure (on and off CPB). No protease inhibitors (aprotinin),
antifibrinolytic agents (aminocaproic acid), or corticosteroids were
used in any patients.
Standard systemic heparinization was used (400 IU/kg), and an
activated clotting time of greater than 450 seconds was maintained
during CPB. CPB was performed with mild-to-moderate hypo-
thermia (30°C-32°C). The extracorporeal circuit consisted of a
roller pump (Jostra), a membrane oxygenator (Capiox SX18,
Terumo), and polyvinyl chloride circuit tubing (Cardio-Re-
search) primed with 2500 mL of isotonic Compound Sodium
Lactate solution (Hartmann’s solution, Baxter) and 10,000 IU
of sodium heparin.
Antegrade cold-blood cardioplegic solution (St Thomas Hos-
pital solution) was used to arrest the heart in diastole. Myocardial
protection was maintained with intermittent cold-blood cardiople-
gic solution (through aortic root and grafts), ice-cold saline topical
cooling, and left ventricular venting (through the aortic root or
right superior pulmonary vein).
An in situ, pedicled, left internal thoracic artery graft to the left
anterior descending artery was used in all patients (n  10). Other
conduits used were aortocoronary long saphenous vein (n  8),
left radial artery (n  3), and in situ, pedicled, right internal
thoracic artery grafts (n  1).
Sample Collection and Storage
Blood samples were taken from the indwelling radial artery cath-
eter to evaluate factors important in systemic EC activation unless
otherwise indicated (Table 1). In addition, left atrial blood was
sampled to most accurately detect inflammatory mediators arising
from pulmonary reperfusion.16 All samples were therapeutically
heparinized (CPB heparin or 5 IU/mL) and contained 0.58% citrate
phosphate dextrose. Samples were kept on ice and then centrifuged
at 3000 rpm for 30 minutes at 4°C, and plasma was removed and
stored at 80°C in 1.5-mL cryotubes (Sarstedt) until analysis.
Hemodilution during CPB was quantified by assaying plasma
protein for each sample. Plasma cytokines and levels of soluble
adhesion molecules were corrected for plasma protein and normal-
ized to that of pre-CPB (control) plasma in each patient.
TABLE 1. Plasma sample collection protocol
Sample Time/description Location
Before CPB Before CPB, after
systemic heparinization
Radial artery catheter
Ischemia During CPB, before AXC
release (ischemia)
CPB arterial line
Reperfusion During CPB, after AXC
release
Left atrium
3 h after 3 h postoperatively Radial artery catheter
24 h after 24 h postoperatively Radial artery catheter
AXC, Aortic crossclamp.
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Human Umbilical Vein Endothelial Cell Isolation
and Cultures
Human umbilical vein endothelial cell (HUVEC) cultures were
harvested by using a modified version of the technique described
by Jaffe and colleagues.17 HUVECs were isolated with collagenase
(Sigma) and grown to confluence in 175-cm2 Falcon tissue-culture
flasks (Becton Dickinson) in Medium 199 (Biosciences) contain-
ing 20% heat-inactivated pooled human serum (CM199), 1% L-
glutamine (Biosciences), 0.5% Endothelial Cell Growth Promoter
(Starrate Pty Ltd), and penicillin-streptomycin (100 IU/0.1 mg/mL,
Sigma). Cells were grown to confluence at 37°C in a 5% CO2
incubator. Cells were subpassaged with 1:250 trypsin/ethylenedi-
amine tetraacetic acid (Biosciences) into 96-well tissue-culture
plates (Falcon, Becton Dickinson), at 10,000 cells/well in 100 L
of media. All glassware was heat treated to ensure an endotoxin-
free system, and media were made up in distilled water (Baxter)
and then filtered with 0.2-m Zetapore filters (Cuno) before use.
All experiments were conducted with passage 2 HUVECs.
Citrate phosphate dextrose (0.58%) was added to all blood
samples to overcome cytotoxic fibrin clot formation on the
HUVEC cultures. In addition, samples were taken during systemic
heparinization or, in the case of postoperative samples, heparin
was added (5 IU/mL). Plasma samples for each patient were
normalized for protein by means of dilution with isotonic crystal-
loid (containing no protein) Compound Sodium Lactate solution
(Hartmann’s Solution, Baxter) to account for hemodilution during
bypass.
HUVEC Expression of Adhesion Molecules
By using a modified technique, as described by other investiga-
tors,2,4,18,19 HUVECs were exposed for 4 hours to 20% patient
plasma and then 20% heat-inactivated pooled human serum. This
allowed for maximal upregulation of adhesion molecule expres-
sion while maintaining normal cell viability. Cell viability was
routinely assessed by means of lactate dehydrogenase release by
monitoring EC morphology with light microscopy and preserva-
tion of cell attachment with quantification of cell protein, as
previously described.20 Under the conditions described, cell via-
bility was preserved (90%-98%, n  6), and cell protein was
greater than 95% of control incubations in pooled, heat-inactivated
serum.
After washing, cell-surface adhesion molecules were measured
with specific enzyme-linked immunosorbent assays (ELISAs) at
4°C, as described by McCrohon and colleagues.19 In brief,
HUVECs were exposed to 1:1000 purified mouse anti-human
monoclonal primary antibodies to CD54 (ICAM-1), CD62E (E-
selectin), and CD106 (VCAM-1; Pharmingen, Becton Dickinson)
in Hanks balanced salt solution containing 10% heat-inactivated
pooled human serum, with an irrelevant, nonmammalian mouse
IgG1 antibody used as a negative control (DAKO). After washing,
cells were incubated with a sheep, anti-mouse horseradish perox-
idase secondary antibody (Amersham, 1:500 dilution), and absor-
bance was read at 405-nm wavelength (Titertek Multiskan MCC
340, Labsystems) after addition of ABTS peroxidase substrate
solution (Kirkegard and Perry Laboratories). For each subject, the
patient’s own pre-CPB plasma (sample 1) incubated with
HUVECs was used as an internal control. Results were expressed
as a percentage of the pre-CPB control (100%) for each subject,
with a mean  SD of quadruplicate cultures for each data point.
Initial experiments established that control cultures incubated with
pooled, heat-inactivated serum and cultures incubated with pre-
CPB plasma demonstrated identical expression of adhesion mol-
ecules.
Commercially available interleukin 1 (IL-1; Pharmingen,
Becton-Dickinson) was used to investigate whether peri-CABG
plasma modulated HUVEC response to IL-1. Stock solution was
diluted and incubated with HUVECs at a final concentration of 1
ng/mL. Preliminary experiments established that this concentration
of IL-1 generated maximal upregulation of adhesion molecule
expression under our experimental conditions.
Soluble Adhesion Molecules and Plasma Cytokines
Plasma soluble adhesion molecule levels (E-selectin, ICAM-1, and
VCAM-1) were measured with commercially available sandwich
ELISAs (Bender MedSystems). Plasma IL-8, IL-10, and trans-
forming growth factor 1 (TGF-1) levels were measured with
commercially available sandwich ELISAs (Pharmingen, Becton-
Dickinson). C-reactive protein (CRP) was measured with an au-
tomated rate nephelometry assay (IMMAGE, Beckman).
Statistical Analysis
All results are expressed as means  SEM (n  10 patients).
Samples were compared with the pre-CPB control. Statistical
analysis was performed with robust cluster multiple linear regres-
sions (STATA 7.0, StataCorp).
Results
Sampling
A detailed plasma sampling protocol was undertaken to
establish the relative importance of ischemia, reperfusion,
and time after CPB in relation to the CPB inflammatory
response (Table 1). Each sample was analyzed for soluble
factors, as well as for its effect on the expression of
VCAM-1, ICAM-1, and E-selectin by HUVECs. Samples
were taken from 10 stable patients undergoing first-time
elective CABG with CPB, with clinical characteristics de-
scribed in Table 2. Of the 10 patients, one required postop-
erative adrenaline, and no patients had a high cardiac out-
put–low systemic vascular resistance state.
Time Course of Systemic Inflammation after CPB
The subjects were first investigated for development of an
inflammatory response typical of CPB. Neutrophil counts
TABLE 2. Clinical characteristics of subjects
Variables Patients (n  10)
No. of patients 10
Male/female 6/4
Age (y) 69 (46-79)
CPB time (min) 81 (56-132)
AXC time (min) 56 (35-69)
Grafts 3 (2-5)
Data are given as median (range).
AXC, Aortic crossclamp.
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were markedly increased 1 hour postoperatively (preopera-
tively, 5.2  0.5  109/L; 1 hour postoperatively, 12.6 
1.1  109/L; P  .001). Concentrations of the potent
neutrophil chemokine IL-8 (Figure 1, A) were significantly
increased in the left atrial reperfusate plasma, and postop-
erative and plasma CRP (Figure 1, B) were increased 24
hours after the operation. Thus plasma IL-8 and neutrophil
counts increased in the early post-CPB phase and preceded
the increase in CRP.
Soluble ICAM-1 and Soluble VCAM-1, but not
Soluble E-selectin, Are Increased Late After CPB
Soluble VCAM-1 (157%  18% relative to before CPB,
P  .0001; Figure 2, A) and ICAM-1 (135%  16%, P 
.02; Figure 2, B) were significantly increased 24 hours
postoperatively. Soluble VCAM-1 and soluble ICAM-1
were not significantly increased in earlier plasma samples,
and their increase occurred later than that of plasma IL-8
and total neutrophil counts, as described above. Soluble
E-selectin (an endothelium-specific adhesion molecule; Fig-
ure 2, C) was unchanged after the operation.
EC Surface Expression of ICAM-1 and VCAM-1 Are
Decreased by Exposure to CPB Plasma
Plasma samples were incubated with HUVECs, and EC
expression of VCAM-1, ICAM-1, and E-selectin was quan-
tified to establish whether factors released into plasma dur-
ing CABG affected EC expression of adhesion molecules.
Relative to control ECs (each subjects’ pre-CPB plasma
exposed to ECs), EC VCAM-1 expression was decreased
when exposed to plasma taken during ischemia and at 3 and
24 hours postoperatively (Figure 3, A). Similarly, ICAM-1
expression was significantly decreased when exposed to
plasma taken 3 hours postoperatively (Figure 3, B). E-
selectin expression was not significantly affected by expo-
sure to any of the perioperative plasma samples.
Post-CPB Plasma Suppresses IL-1-mediated
Upregulation of VCAM-1 and ICAM-1
The downregulation of HUVEC cell-surface expression of
VCAM-1 and ICAM-1 by post-CPB plasma might be due to
a deficiency of stimulatory factors or to the presence of
factors that actively suppressed expression. ECs were incu-
Figure 1. Proinflammatory mediators are increased in circulating plasma after CPB: A, plasma IL-8; B, plasma CRP.
Samples are defined in Table 1. *P < .05, **P < .01, and ***P < .001 relative to preoperative values (sample 1).
Data are given as means  SEM (n  10).
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bated with CPB samples in the presence of the proinflam-
matory cytokine IL-1 to investigate this.
As expected, IL-1 increased cellular expression of E-
selectin, ICAM-1, and VCAM-1 by HUVECs by between 3-
and 6-fold (Figure 4, A). However, the IL-1-mediated in-
crease of VCAM-1 (Figure 4, B) was inhibited by plasma
taken 3 hours postoperatively and 24 hours postoperatively.
Similarly, the IL-1-mediated increase of ICAM-1 was inhib-
ited by plasma taken 24 hours postoperatively (Figure 4, C).
Expression of E-selectin (Figure 4, D) by IL-1-activated
HUVECs was not significantly affected by exposure to any of
the patients’ plasma samples. Importantly, although the
Figure 2. Plasma-soluble VCAM-1 and ICAM-1 increase after CPB: A, VCAM-1; B, ICAM-1; C, E-selectin. Samples
are defined in Table 1. **P < .01 and ***P < .001 relative to preoperative values (sample 1). Data are given as
means  SEM (n  10).
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stimulatory effect of IL-1 on ICAM-1 and VCAM-1 ex-
pression was blunted, IL-1 still exerted a significant stim-
ulatory effect on cellular adhesion molecule expression in
the presence of post-CPB plasma. These data indicate that
post-CPB plasma might contain factors that actively inhibit
IL-1-mediated ICAM-1 and VCAM-1 expression.
Plasma TGF-1 and IL-10 Are Increased After CPB
Factors known to be capable of actively downregulating EC
surface expression of ICAM-1 and VCAM-1 were investi-
gated. TGF-1 and IL-10 have been identified as inhibitors
of EC adhesion molecule expression in many non-CPB
states.21,22 We hypothesized that they might contribute to
Figure 3. HUVEC cell-surface VCAM-1 and ICAM-1 expression is suppressed by post-CPB plasma. HUVEC
monolayers were incubated with CPB plasma. Cellular adhesion molecule expression was quantified by means of
ELISA and expressed as a percentage of their expression on HUVECs incubated with pre-CPB plasma of the same
subject (sample 1). Samples are defined in Table 1. *P < .05 and **P < .01 relative to preoperative values (sample
1). Data are given as means  SEM (n  10).
Vallely et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 4 763
CS
P
Figure 4. IL-1-activated HUVEC VCAM-1 and ICAM-1 expression is suppressed by post-CPB plasma: A, upregu-
lation of HUVEC expression of VCAM-1, ICAM-1, and E-selectin by IL-1 in the presence of control preoperative
plasma (P < .001 for comparison of control with IL-1 for each adhesion molecule); B-D, effect of post-CPB plasma
on IL-1-stimulated expression of VCAM-1 (B), ICAM-1 (C), and E-selectin (D). All values are expressed as a
percentage expression of IL-1-exposed pre-CPBB plasma (sample 1). Samples are defined in Table 1. *P < .05,
**P < .01, and ***P < .001 relative to preoperative values (sample 1). Data are given as means  SEM (n  10).
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CPB-mediated suppression and investigated this possibility
irrespective of whether they were increased after CPB.
TGF-1 at 3 hours was significantly increased 3 hours
postoperatively (2.9-fold relative to before CPB; Figure 5,
A). IL-10 was significantly increased during CPB after
aortic crossclamp release during early reperfusion (9.8-fold)
and maximally increased 3 hours postoperatively (14-fold;
Figure 5, B). The increase of IL-10 was relatively short
lived, whereas the TGF-1 increase was sustained.
Discussion
Inflammation after CABG is understood to involve activa-
tion of the endothelium; however, the relative importance of
endothelial expression of cell-surface adhesion molecules in
this process is unclear. This study is the first to relate EC
expression of adhesion molecules to their concentration in
plasma after CABG, and suggests that the two are dissoci-
ated.
A number of studies have investigated soluble plasma
adhesion molecules after CABG.5-7,23 Although some indi-
cate a null effect,8 the majority indicate upregulation of
soluble adhesion molecules after CPB.5,24 Our data supports
this in relation to ICAM-1 and VCAM-1, particularly in
samples taken 24 hours postoperatively. This was not found
for E-selectin.
The difference between ICAM-1, VCAM-1, and E-se-
lectin might indicate that the release of ICAM-1 and
VCAM-1 from cells other than endothelium might contrib-
ute to plasma soluble adhesion molecules. E-selectin, in
contrast to ICAM-1 and VCAM-1, is endothelium specific.
Alternatively, the release of E-selectin might be relatively
short lived, and time points used in our study might have
failed to collect plasma samples containing the highest
amounts of E-selectin.
That soluble ICAM-1 and soluble VCAM-1 were in-
creased late after surgical intervention does not suggest their
acute release during ischemia or reperfusion during CPB.
Other markers of systemic inflammation (polymorphonucle-
ar neutrophil count and IL-8) preceded the soluble ICAM-1
and soluble VCAM-1 increase. These kinetic considerations
suggest that if EC activation explains the presence of solu-
ble ICAM-1 and soluble VCAM-1 after CABG, it might
follow other inflammatory processes, such as neutrophil
activation. Because all patients underwent operations with
Figure 5. Plasma TGF-1 and IL-10 are increased after CPB: A, TGF-1; B, IL-10. Samples 1 to 5 are defined in Table
1. *P < .05, **P < .01, and ***P < .001 relative to preoperative values (sample 1). Data are given as means  SEM
(n  10).
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CPB, we cannot delineate the role of the bypass circuit in
influencing soluble ICAM-1 and VCAM-1. A comparative
study with patients undergoing surgical intervention without
CPB would be interesting.
In our study an IL-8 increase preceded postoperative
neutrophilia, and this preceded an increase in CRP. This
sequence is to be expected because IL-8 is a neutrophil
chemokine and CRP represents the later effects of systemic
inflammation on the liver. The late increase of CRP suggests
ongoing inflammation 24 hours postoperatively, which is
consistent with previous literature.25 The more rapid decline
of IL-10 postoperatively relative to TGF-1 is interesting
and unexplained. It suggests that different stimuli (eg, reper-
fusion injury for IL-10)22 are responsible for upregulation of
these 2 inflammatory mediators.
The most remarkable finding in the present study was the
suppression of EC ICAM-1 and VCAM-1 expression by
post-CABG plasma. This cannot be attributed to an atypical
patient population because soluble adhesion molecules and
typical systemic inflammatory markers were increased after
CABG. The postoperative increase in soluble adhesion mol-
ecules and the suppression of EC adhesion molecules might
indicate a relationship between the 2 processes. It is possible
that soluble adhesion molecules are released from the cell
surface as a result of cleavage or shedding26 and that their
increased plasma concentration represents increased release
from the cell surface rather than increased cell expression.
Because ICAM-1 and VCAM-1 are constitutively expressed
on resting endothelium, and E-selectin expression is in-
duced by activation of the endothelium, our data might
support cleavage of cell-surface adhesion molecule rather
than increased EC synthesis and cell-surface expression.
Alternatively, the increase in soluble adhesion molecules
and decreased EC adhesion molecule expression might both
be independent consequences of earlier inflammatory pro-
cesses, such as neutrophil activation and cytokine release. In
addition, future studies might identify whether other EC
lines, such as microvascular cell lines27 or arterial cells,28
respond differently to HUVECs when exposed to peri-
CABG plasma. Similarly, it is possible that other adhesion
molecules, such as P-selectin, might behave differently than
the adhesion molecules in our study.
The blunting of the IL-1-mediated expression of EC
ICAM-1 and VCAM-1 (but not E-selectin) suggests that
there might be factors released into post-CABG plasma that
inhibit ICAM-1 and VCAM-1 expression. One possible
mechanism by which plasma antagonizes the effect of
IL-1 is the presence of IL-1 receptor antagonist, which can
be present after CPB.29 Second, TGF-1 and IL-10 both
suppress adhesion molecule expression30,31 and were both
increased in our population, which is consistent with a
possible role for these cytokines in suppressing EC adhesion
molecule expression by post-CPB plasma.
The findings of this study have important clinical impli-
cations. First, they dissociate soluble adhesion molecule
concentrations from plasma-induced EC expression. Sec-
ond, they suggest that prevention of EC E-selectin,
ICAM-1, or VCAM-1 upregulation might not be a suitable
therapeutic target for the reduction of inflammation after
CPB. However, inhibition of their expression or activity
might still have a role. Third, they suggest that EC activa-
tion after CPB is not an indiscriminate process and that
mediators of irreversible leukocyte adhesion (ICAM-1 and
VCAM-1), and not reversible adhesion (E-selectin), are
differentially modulated after CPB. Future targeting of the
post-CPB systemic inflammatory response will require elu-
cidation of mechanisms underlying these observations.
We thank Gail de Lucia, RN, for her invaluable help in con-
ducting this study and Jack Chen, PhD, for his statistical analyses.
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